- In May 2024, Atara Biotherapeutics submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel) as a proposed standalone treatment for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) in adults and children aged 2 years and older, who have previously received at least one therapy. The submission of this BLA underscores the increasing role of precision medicine in targeting specific, hard-to-treat diseases
- In May 2024, Dragonfly Therapeutics, Inc., a biotechnology company focused on developing innovative immunotherapies, announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada). The integration of targeted therapies, such as DF9001 and KEYTRUDA, highlights the growing importance of precision medicine in oncology, offering highly personalized treatment approaches that are tailored to the genetic and molecular characteristics of individual tumors
- In January 2024, BIOS Health announced a strategic partnership with the Kern Venture Group to establish a precision medicine hub in Bakersfield, California. This collaboration aims to foster innovation in personalized healthcare by advancing research and development efforts in precision medicine, ultimately improving patient outcomes in the region. This partnership aligns with the global trend of expanding precision medicine initiatives, which are increasingly recognized for their ability to deliver tailored treatments based on individual genetic profiles and specific disease characteristics
- In November 2023, Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) approval of Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The approval of Augtyro represents a significant milestone in the field of precision medicine, as it highlights the increasing importance of targeted therapies based on specific genetic biomarkers, such as ROS1 mutations
- In February 2022, Oncodesign and SEngine Precision Medicine Inc. entered into a research collaboration agreement aimed at developing advanced, personalized cancer therapies for patients suffering from aggressive and untreatable cancers. The collaboration underscores the growing importance of precision medicine in oncology, emphasizing the shift toward personalized, targeted therapies
